Coherus Oncology (CHRS) Non-Current Deffered Revenue (2013 - 2017)

Coherus Oncology has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $725000.0 in Q1 2017.

• Quarterly Non-Current Deffered Revenue fell 97.8% year-over-year to $725000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $725000.0 (down 97.8% YoY) and the FY2016 annual result came in at $669000.0, down 98.52% from the prior year.
• Non-Current Deffered Revenue improved to $725000.0 in Q1 2017 per CHRS's latest filing, from $669000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $45.3 million in Q4 2015 and troughed at $595000.0 in Q3 2016.
• A 5-year average of $27.1 million and a median of $33.2 million in 2015 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2014 and 2016: Non-Current Deffered Revenue soared 39.67% in 2014, then tumbled 98.52% in 2016.
• Over 5 years, Non-Current Deffered Revenue stood at $28.6 million in 2013, then surged by 39.67% to $39.9 million in 2014, then rose by 13.63% to $45.3 million in 2015, then sank by 98.52% to $669000.0 in 2016, then rose by 8.37% to $725000.0 in 2017.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $725000.0, $669000.0, and $595000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.